|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2004-8-31
|
|
pubmed:abstractText |
Antibody treatment is considered tolerable and potentially effective in the therapy of neuroblastoma. We have analyzed stage 4 neuroblastoma patients older than 1 year who underwent consolidation treatment with the chimeric monoclonal anti-GD2-antibody ch14.18.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3549-57
|
|
pubmed:dateRevised |
2011-7-29
|
|
pubmed:meshHeading |
pubmed-meshheading:15337804-Adolescent,
pubmed-meshheading:15337804-Adult,
pubmed-meshheading:15337804-Antibodies, Monoclonal,
pubmed-meshheading:15337804-Child,
pubmed-meshheading:15337804-Child, Preschool,
pubmed-meshheading:15337804-Disease-Free Survival,
pubmed-meshheading:15337804-Female,
pubmed-meshheading:15337804-Humans,
pubmed-meshheading:15337804-Infant,
pubmed-meshheading:15337804-Male,
pubmed-meshheading:15337804-Neoplasms, Unknown Primary,
pubmed-meshheading:15337804-Neuroblastoma,
pubmed-meshheading:15337804-Retrospective Studies,
pubmed-meshheading:15337804-Survival Rate,
pubmed-meshheading:15337804-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
|
|
pubmed:affiliation |
Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Germany. thorsten.simon@uk-koeln.de
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
